SOURCE: Market Pulse

February 03, 2010 08:30 ET

Market Pulse Breaking News Alert for Wednesday, February 3, 2010: RMCP -- RevMed Achieves Major Milestones and Provides a Very Optimistic Outlook for 2010!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA--(Marketwire - February 3, 2010) - Market Pulse News Alert for this AM, Stocks to Watch are: Revolutions Medical Corporation (OTCBB: RMCP), SIRIUS XM Radio Inc. (NASDAQ: SIRI), Medical Connections Inc. (OTCBB: MCTH) and BSD Medical Corp. (NASDAQ: BSDM).

Investors need to be watching Revolutions Medical Corporation (OTCBB: RMCP) this AM! Revolutions Medical Corporation (RevMed) is engaged in the design, development, commercialization and acquisition of new products and tools to make healthcare safer and less expensive. RevMed's products include safety-engineered medical devices (SEMDs) and the flagship RevVac safety syringe (FDA Approved), safety blood drawing devices, and safety IV catheters. The products use a proprietary patented technology in which a vacuum causes the needle to retract into the barrel of the syringe or device after an injection is administered or blood is drawn. RevMed owns the patents to manufacture the disposable retractable syringe and phlebotomy device. The world market for SEMDs is projected to exceed $2 billion this year and is forecasted to maintain a 20% annual growth rate in the near term. RevMed also offers RevColor, RevDisplay and Rev3D, software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D, and automatic segmentation of images. These tools will enhance the physician's diagnostic confidence in an industry that is growing at 10% - 15% (more than 25 million procedures) per year with a worldwide market potential for these tools that exceeds $3.5 billion. The company is continually looking for new and improved technology through internal product development and acquisition. The company's future growth will be powered by new product line introductions, and the material expansion of existing successful lines. RevMed's Breast Biopsy System (BBS), stereotactic (minimally invasive) image-based localization technology, is one of those product lines pursuing the $9.5 billion breast screening industry. RevMed's Breast Biopsy System, the MRI enhancement software and the SEMDs will be launching in the next 18 months. All three markets are immediately addressable and total more than $14 billion. RevMed recently introduced its proprietary suite of MRI software products at the Radiology Society of North America annual meeting with great success. Radiologists and universities world-wide received presentations at the RMCP booth. A number of these contacts could play an important role in the company's ongoing efforts to clinically validate specific applications of its MRI tools prior to the 2010 commercial launch. Never has health care been a hotter issue, and the focus of the conversation is on increased safety at dramatically reduced cost. Revolutions Medical has the formula for success, and one that has them immediately positioned for a high growth future. With 3 recurring revenue business lines with blended gross margins projected to exceed 50% and anticipated profitability in its first full year of operations, Revolutions Medical Corporation is poised to become a significant player in the healthcare and medical devices industry! RMCP just had excellent news out in a press release before today's opening bell announcing a recap of important milestones achieved in 2009 and offered a very optimistic corporate outlook for 2010! Investors should be watching this one closely!

Revolutions Medical Corporation (OTCBB: RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, today provided a recap of important milestones achieved in 2009 and offered a corporate outlook for 2010 through the following open letter to shareholders:

From the Desk of RevMed CEO Ron Wheet

Dear RevMed Shareholders,

This last year was truly a watershed one for RevMed, and it has brought us a great distance towards the commercial launch of the RevVac safety syringe, and the subsequent launch of our revolutionary suite of color MRI software. Consistent with our commitment to proactive investor communication, we would like to recap the past year and provide a brief outlook for 2010.

Fiscal Year 2009

This last year saw horrific market conditions, a plague of business failures and consumers everywhere tightening their belts. Yet the medical industry continued to expand. Revolutions Medical not only weathered the storm but was successful in raising capital and meeting its short term operational objectives. We reached the tipping point of launching our two core recurring revenue business lines. We believe we have laid the foundation in 2009 to achieve profitability in our first full year of distribution and sales; we began the transition from a company developing products to one manufacturing and distributing potential market game-changers, and to a company poised to generate real revenue and earnings.

Looking briefly to 2008 and continuing through 2009 we have achieved the following:

--  Ascended to the Over-the-Counter Bulletin Board and acquired 100% of
    Clear Image Acquisition Corporation, the developer of our MRI software

--  To date, approximately $3 MM has been invested toward RevColor and
    Rev 3D MRI product development

--  To date, approximately $3 MM  has been invested toward the RevVac
    Safety Syringe product development

--  Received FDA 510K clearance for the RevVac safety syringe

--  Launched the initial steps of RevVac manufacturing process for the
    3ml safety syringe

--  Forged a distribution partnership with Libra International in South
    America -- the first of many targeted worldwide syringe markets

--  Began cultivating relationships with more than 50 distributors
    worldwide and now will initiate the process of signing distribution
    agreements with those that fit our criteria to distribute our products

--  Introduced the MRI suite of products on the imaging technology and
    software world stage at the Radiological Society of North America
    (RSNA) in Chicago

--  Signed RevMed President Tom O'Brien, acclaimed pioneer in MRI
    sales/marketing and the former CEO of private and public medical
    companies, to a 3-year employment agreement

--  Opened our new corporate office at:
        670 Marina Drive, Third Floor
        Charleston, SC 29492

--  Appointed distinguished law firm Anslow & Jaclin, LLP as legal
    counsel, represented by firm partner Joseph M. Lucosky, Esq.

--  Hired the accredited accounting firm Elliott Davis LLC

--  Engaged Cirrus Financial Communications as our external Investor
    Relations Officer.

Fast Facts

Prior to our 2010 outlook and in response to investor inquiries, we would like to take this opportunity to reiterate some fundamental company information.

        Capital Structure and Balance Sheet

        --  Basic shares outstanding: 33.1 MM
        --  Fully diluted shares outstanding: 43.2 MM
        --  Approximate float: 24.0 MM shares
        --  52-week range: $0.14 - $0.71
        --  No long term debt

        Intellectual Property (IP)

        RevMed has secured multiple design, technology and process patents,
        and has filed to receive many more -- we are confident that we
        enter the market substantially protected, and will only further
        secure our defense against competition in the months to come. To
        date, we can claim the following:

              --  Image Enhancement: 4 U.S. and 2 international patent
                  applications filed

              --  Safety Syringe: 4 U.S. patents awarded and
                  7 international patent applications filed

              --  Blood Drawing Device: 1 U.S. patent awarded

Fiscal Year 2010

We are very optimistic about 2010, and below are some anticipated items/initiatives of note for the coming year:

--  Sign up distributors nationally and worldwide

--  License additional syringe manufacturers

--  Integrate MRI tools into a delivery platform

--  Receive validation of MRI tools with major teaching hospitals and
    experts in the various applicable fields of medicine

--  Confirm additional MRI diagnostic applications such as Alzheimer's,
    concussion, cardiac disease and breast disease

--  Negotiate agreements with other equipment manufacturers and value-added

--  Set up, packaging and quality assurance in Charleston, South Carolina

--  Continue to expand family of safety syringes, blood drawing devices and
    other products in aesthetics, etc

--  Continue to build management team, adding a Chief Technology Officer,
    International Sales Manager and others as appropriate

In closing, we would like to thank you all for your past support, continued interest, and in many cases, your dedication and patience. After years of research and development, we believe our vision will become reality in 2010. Never has health care been a more important issue, and the focus of the conversation is on increased safety at dramatically reduced cost. We feel that RevMed is perfectly positioned to capitalize on this vital need through our two immediate product line opportunities.

About Revolutions Medical Corporation (

RevMed's products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. RevMed also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.

Investor Resource Center

Fact Sheet:

CEO Ron Wheet Audio Interview:

RevVac Demo Video:

Stocks in the news and acting well as of late include: SIRIUS XM Radio Inc. (NASDAQ: SIRI), Medical Connections Inc. (OTCBB: MCTH) and BSD Medical Corp. (NASDAQ: BSDM).

Information contained herein is the opinion of ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated twenty five thousand restricted shares of Revolutions Medical Corporation by the company. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information